

27 October 2026

cyclopharm



cyclomedica technegas

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

Cyclopharm Ltd ABN 74 116 931 250  
Unit 4, 1 The Crescent Kingsgrove NSW 2208 Australia  
T 61 2 9541 0411  
F 61 2 9543 0960  
www.cyclopharm.com.au

## Cyclopharm Q3 Investor Update Webinar

**Sydney, October 27, 2026:** Cyclopharm Limited (ASX: CYC), a global leader in functional lung ventilation imaging, is pleased to announce it will host a webinar to provide an update on the Company's activities and progress during Q3 FY26.

The webinar will be held at **11:00am (AEDT) on Thursday 29 October 2026**.

CEO and Managing Director James McBrayer will present the update, and shareholders, investors and interested parties are encouraged to **register to attend the presentation at the following link:**

[https://us02web.zoom.us/webinar/register/WN\\_ykJAMTiaRHqiqJfRWRdJ7g](https://us02web.zoom.us/webinar/register/WN_ykJAMTiaRHqiqJfRWRdJ7g)

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that wish to join by phone.

Questions can be submitted live during the webinar or sent in advance to: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Please note a replay of the webinar will be available at the above-mentioned link shortly following the conclusion of the live session.

This ASX announcement was authorised for release by James McBrayer, Managing Director, CEO and Company Secretary

**For further information: James McBrayer, Managing Director, CEO and Company Secretary, Cyclopharm Limited  
– T: +61 (02) 9541 0411**

### Cyclopharm Limited

Cyclopharm is an ASX-listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas, used in functional lung ventilation imaging.

### Technegas®

The Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro-furnaced for a few seconds at around 2,700 °C. The resultant gas-like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional lung ventilation. Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology, multimodality imaging, and analytical software, is being investigated and applied in other disease states, including COPD, asthma, pulmonary hypertension, and certain interventional applications, such as lobectomies in lung cancer and lung volume reduction surgery.

In the United States, Technegas® is indicated for the visualization of pulmonary ventilation and for the evaluation of pulmonary embolism when paired with perfusion imaging, in adults and paediatric patients aged 6 years and older. Please refer to the full US Prescribing Information for approved uses, important safety information and radiation dosimetry.